

Ballymun Local Drugs Taskforce Company Limited By Guarantee
Annual Report and Financial Statements
for the financial year ended 31 December 2024

Company Number: 376627

Ballymun Local Drugs Taskforce Company Limited By Guarantee

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Income Statement	10
Statement of Financial Position	11
Statement of Changes in Equity	12
Statement of Cash Flows	13
Notes to the Financial Statements	14 - 17

**Ballymun Local Drugs Taskforce Company Limited By Guarantee
DIRECTORS AND OTHER INFORMATION**

Directors	Andrew Montague Fiona Descoteaux Mary Taylor - Chairperson
Company Secretary	Patrick White
Company Number	376627
Charity Number	CHY 15954
Registered Office and Business Address	C/O Axis Main Street Ballymun Dublin 9 Ireland
Auditors	KSi Faulkner Orr Limited Behan House, 10 Lower Mount Street, Dublin 2.
Bankers	Allied Irish Banks, 53 Main Street, Finglas, Dublin 11.
Solicitors	MacGeehin Toale Nagle, 10 Prospect Road, Glasnevin, Dublin 9.

Ballymun Local Drugs Taskforce Company Limited By Guarantee

DIRECTORS' REPORT

for the financial year ended 31 December 2024

The directors present their report and the audited financial statements for the financial year ended 31 December 2024.

Principal Activity

The principal activity of the company consists of overseeing the delivery of a comprehensive and integrated strategy to promote the prevention of drug taking, the reduction of drug supply and the treatment and rehabilitation of drug users; bringing together of local people and statutory agencies to develop and implement this strategy. The company has received charitable status from the Revenue Commissioners (Charity Number CHY 15954).

The Company is limited by guarantee not having a share capital.

Principal Risks and Uncertainties

The directors consider that the following are the principal risk factors that could materially and adversely affect the company's future operating results or financial position:

- Withdrawal of support from major funders.
- Economic recession.

The company has organisational policies and structures to limit some of these risks and the Board of Directors and Management regularly review, reassess and proactively limit the associated risks insofar as possible.

Financial Results

The surplus for the financial year amounted to €44,452 (2023 - €44,422).

At the end of the financial year, the company has assets of €285,952 (2023 - €251,166) and liabilities of €58,107 (2023 - €67,773). The net assets of the company have increased by €44,452.

Directors and Secretary

The directors who served throughout the financial year were as follows:

Andrew Montague
Fiona Descoteaux
Mary Taylor - Chairperson

The secretary who served throughout the financial year was Patrick White.

Future Developments

The company has developed an established place for itself within its market and will continue developments in this area.

Post Statement of Financial Position Events

There have been no significant events affecting the company since the financial year-end.

Auditors

The auditors, KSI Faulkner Orr Limited have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

Ballymun Local Drugs Taskforce Company Limited By Guarantee DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2024

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


Disclosure of Information to Auditor

Each persons who are directors at the date of approval of this report confirms that:

- there is no relevant audit information (information needed by the company's auditor in connection with preparing the auditor's report) of which the company's auditor is unaware, and
- the directors have taken all the steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Signed on behalf of the board

Andrew Montague
Director



Mary Taylor - Chairperson
Director



21 November 2025

Ballymun Local Drugs Taskforce Company Limited By Guarantee
DIRECTORS' REPORT

for the financial year ended 31 December 2024

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at C/O Axis, Main Street, Ballymun, Dublin 9.

Signed on behalf of the board

Andrew Montague
Director



Mary Taylor - Chairperson
Director



21 November 2025

INDEPENDENT AUDITOR'S REPORT

to the Members of Ballymun Local Drugs Taskforce Company Limited By Guarantee

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Ballymun Local Drugs Taskforce Company Limited By Guarantee ('the company') for the financial year ended 31 December 2024 which comprise the Income Statement, the Statement of Financial Position, the Statement of Changes in Equity, the Statement of Cash Flows and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2024 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 3 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Members of Ballymun Local Drugs Taskforce Company Limited By Guarantee

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 6, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.


Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Emma Delaney

for and on behalf of

KSI FAULKNER ORR LIMITED

Statutory Auditors

Behan House,

10 Lower Mount Street,

Dublin 2.

21 November 2025

Ballymun Local Drugs Taskforce Company Limited By Guarantee APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control's relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Ballymun Local Drugs Taskforce Company Limited By Guarantee


INCOME STATEMENT

for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Income		600,842	586,086
Expenditure		(556,390)	(541,664)
Surplus for the financial year		<u>44,452</u>	<u>44,422</u>
Total comprehensive income		<u><u>44,452</u></u>	<u><u>44,422</u></u>

Approved by the board on 21 November 2025 and signed on its behalf by:

Andrew Montague
Director



Mary Taylor - Chairperson
Director



Ballymun Local Drugs Taskforce Company Limited By Guarantee
STATEMENT OF FINANCIAL POSITION



as at 31 December 2024

	Notes	2024 €	2023 €
Current Assets			
Debtors	6	8,000	-
Cash and cash equivalents		277,952	251,166
		<u>285,952</u>	<u>251,166</u>
Creditors: amounts falling due within one year	8	(58,107)	(67,773)
Net Current Assets		<u>227,845</u>	<u>183,393</u>
Total Assets less Current Liabilities		<u>227,845</u>	<u>183,393</u>
Reserves			
Retained surplus		227,845	183,393
Members' Funds		<u>227,845</u>	<u>183,393</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on 21 November 2025 and signed on its behalf by:

Andrew Montague
Director

Mary Taylor - Chairperson
Director

Ballymun Local Drugs Taskforce Company Limited By Guarantee
STATEMENT OF CHANGES IN EQUITY

as at 31 December 2024

	Retained surplus	Total
	€	€
At 1 January 2023	138,971	138,971
Surplus for the financial year	44,422	44,422
At 31 December 2023	183,393	183,393
Surplus for the financial year	44,452	44,452
At 31 December 2024	<u>227,845</u>	<u>227,845</u>

Ballymun Local Drugs Taskforce Company Limited By Guarantee
STATEMENT OF CASH FLOWS

for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Cash flows from operating activities			
Surplus for the financial year		44,452	44,422
		<u>44,452</u>	<u>44,422</u>
Movements in working capital:			
Movement in debtors		(8,000)	280
Movement in creditors		(9,666)	(43,693)
		<u>26,786</u>	<u>1,009</u>
Cash generated from operations			
		<u>26,786</u>	<u>1,009</u>
Net increase in cash and cash equivalents		26,786	1,009
Cash and cash equivalents at beginning of financial year		251,166	250,157
		<u>277,952</u>	<u>251,166</u>
Cash and cash equivalents at end of financial year	7	<u>277,952</u>	<u>251,166</u>

Ballymun Local Drugs Taskforce Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

1. General Information

Ballymun Local Drugs Taskforce Company Limited By Guarantee is a company limited by guarantee incorporated in Ireland. C/O Axis, Main Street, Ballymun, Dublin 9, Ireland is the registered office, which is also the principal place of activity of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2024 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income

Income is accounted for an accruals basis, except for subscriptions and donations, which are accounted for when received.

Governments Grants

Revenue grants are credited to deferred revenue and are released to the income and expenditure account as the related expenditure is incurred.

Capital grants are released to the income and expenditure account over the expected useful life of the assets to which they relate.

Significant accounting judgements and key sources of estimation uncertainty

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The only judgements and estimations included in the financial statements are those which relate to depreciation of non-current assets. The directors are of the opinion that the depreciation is appropriate and the net book value of the assets are reasonable

Property, plant and equipment and depreciation

From 1st January 2015 the company's policy is not to capitalise fixed assets amounts under €5,000.

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight Line
----------------------------------	---	-------------------

Ballymun Local Drugs Taskforce Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

The company is a registered charity and exempt from Corporation Tax.

3. Provisions Available for Audits of Small Entities

In common with many other businesses of our size and nature, we use our auditors to assist with the preparation of the financial statements.

4. Employees

The average monthly number of employees, including directors, during the financial year was 4. (2023 - 4).

	2024 Number	2023 Number
Administration	4	4
	<u>4</u>	<u>4</u>
5. Property, plant and equipment		
	Fixtures, fittings and equipment €	Total €
Cost		
At 1 January 2024	265	265
	<u>265</u>	<u>265</u>
At 31 December 2024	265	265
	<u>265</u>	<u>265</u>
Depreciation		
At 1 January 2024	265	265
	<u>265</u>	<u>265</u>
At 31 December 2024	265	265
	<u>265</u>	<u>265</u>
Net book value		
At 31 December 2024	-	-
	<u>-</u>	<u>-</u>
6. Debtors	2024 €	2023 €
Accrued income	8,000	-
	<u>8,000</u>	<u>-</u>
7. Cash and cash equivalents	2024 €	2023 €
Cash and bank balances	277,952	251,166
	<u>277,952</u>	<u>251,166</u>

Ballymun Local Drugs Taskforce Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

8. Creditors	2024	2023
Amounts falling due within one year	€	€
Taxation	7,425	5,388
Other creditors	1,747	3,854
Accruals	20,721	21,517
Deferred Income	28,214	37,014
	<u>58,107</u>	<u>67,773</u>

9. State Funding

Agency	Dublin City Council
Government Department	Department of Health (Drugs Programmes Unit)
Grant Programme	Local Drugs and Alcohol Task Force Interim Funding
Purpose of the Grant	Ballymun Community Initiatives Project
Term	31 December 2024
Total Fund	€284,716
Fund deferred or due at financial year end	€0
Received in the financial year	€284,716
Capital Grant	No
Agency	Health Service Executive
Government Department	HSE Social Inclusion
Grant Programme	Local Drugs and Alcohol Task Force Interim & Mainstream Funding
Purpose of the Grant	Ballymun Prevention Projects; Ballymun Admin Project; Treatment & Rehabilitation Fund; Policy & Research Officer; Strand 1 of Community Healthcare Initiatives; City Clinic Healthcare Fund.
Term	31 December 2024
Total Fund	€302,725
Fund deferred or due at financial year end	€0
Received in the financial year	€302,725
Capital Grant	No
Agency	Department of Justice
Government Department	Department of Justice
Grant Programme	Community Safety Innovation Fund Grant
Purpose of the Grant	Base Bus Ballymun
Term	2024/2025
Total Fund	€120,000
Fund deferred	€28,214
Released in the financial year	€13,401
Capital Grant	Yes

10. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 1.

11. Capital commitments

The company had no material capital commitments at the financial year-ended 31 December 2024.

Ballymun Local Drugs Taskforce Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

12. Related party transactions

There were no transactions with the directors during the year.

Fiona Descoteaux is a director of the Axis Centre where the Ballymun Local Drugs Task Force CLG office is located. As well as renting premises in Axis, Ballymun Local Drugs Taskforce CLG from time-to-time hire conference facilities from it and sometimes commission performances etc. in the Axis arts and theatre space.

13. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

14. Wages and salaries	2024	2023
	€	€
Wages and salaries	169,289	185,024
Social security costs	17,664	20,443
	<u>186,953</u>	<u>205,467</u>

There was one employee who earned over €60,000 for the reporting period.

Between €60,000 - €70,000: 1 (2024), 1 (2023).

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 21 November 2025.

